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Bcl-2 as a Predictive Factor for Biochemical Recurrence
after Radical Prostatectomy: An Interim Analysis
I n t r o d u c t i o n
The early detection of prostate cancer with prostate specific
antigen (PSA) testing allows many patients the option of radical
treatment with curative intent. However, approximately 25% of
patients will develop a post-operative biochemical recurrence (BCR) (1).
The prognosis after radical prostatectomy (RP) is usually based on
clinical findings, such as the pre-operative PSA level and PSA doubling
time, pathologic findings, such as the Gleason score, surgical margin
status (SMS), extraprostatic extension, and seminal vesicle invasion
(SVI) (1-5). Furthermore, several investigators have reported the
usefulness of nomograms in calculating survival after definitive
therapy for localized prostate cancer, which were developed based
on multiple clinical parameters. To date, numerous attempts have
been made to use tissue biomarkers to enhance the prediction of
outcome after RP. However, no molecular markers have been identified
that contribute independent prognostic information on prostate
specimens to enable prediction of treatment failure after RP. Many
potentially prognostic markers have been studied, and some have
been incorporated into prognostic models or therapeutic decision
making. The oncoprotein encoded by the Bcl-2 gene is well-accepted
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Purpose
The objective of this study was to determine Bcl-2 expression in localized prostate cancer
and its potential role as a predictive factor for biochemical recurrence (BCR).
Materials and Methods
This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate
who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center
between February 2005 and May 2009. RP specimens obtained from these patients were
analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other
clinicopathologic factors were evaluated. Statistical analysis was performed with contingency
table analysis, chi-square tests, and a Cox proportional hazard model.
Results
Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression
was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had
a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among
several variables, a high Gleason score in the RP specimen (≥8), extraprostatic extension,
seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were
significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards
analysis revealed that BCR was significantly associated with a high prostate specific antigen
level (p=0.047), SVI (p＜0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012).
Conclusion
Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting
a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of
outcome after RP. 
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for its involvement in the development of human follicular B-cell
lymphomas (6). Likewise, this gene is suspected of participating in
the development of other types of human malignancies (lymphomas,
and breast and prostate cancer) (7-9). Unlike in breast cancer and
lymphoma, a report by Berges et al. (10) suggests that p53 gene ex-
pression is not required to mediate programmed cell death in androgen-
deprived prostatic glandular epithelial cells in prostate cancer. Further-
more in clinical specimens, it is not clear that p53 and bcl-2 necessarily
interact in apoptosis mechanisms. Bauer et al. (11) reported that only
3 of 40 (7.5 percent) adenocarcinoma specimens of the prostate
exhibited combined p53 and bcl-2 positivity. Bcl-2 overexpression
is a relatively low-frequency event in clinically localized prostate
cancer. In addition, bcl-2 showed higher specificity and positive
predictive value than that of p53. Thus, in prostate cancer, we think
that bcl-2 could be an independent biomarker.
In this study, we analyzed the expression of Bcl-2 in a group of
Korean patients to ascertain the clinical significance of Bcl-2
expression in relation to BCR after RP.
M a t e r i a l s  a n d  M e t h o d s
1 Study population
One hundred and seventy-one Korean men, 49-80 years of age,
with clinically localized adenocarcinoma of the prostate were
included in this study. The patients underwent RP at the Korean
National Cancer Center (NCC) between February 2005 and May
2009. None of the patients received androgen deprivation therapy
before RP. All patients had a pre-treatment serum PSA, which ranged
from 0.8 to 79 ng/mL (mean, 9.8 ng/mL). TNM (primary tumor,
regional nodes, metastasis) classification was performed according
to the 2002 American Joint Committee on Cancer. The margin was
considered positive when cancer cells were detected in ≥1 surgical
margins.
In accordance with the requirements of our institutional review
board, informed consent to the prospective study was obtained from
each patient, and the study design was approved by the Research
Ethics Committee of our institution. The mean duration of follow-up
after RP was 23.3 months (range, 2 to 51 months). After RP, patients
were followed up by measurements of serum PSA levels at ≤3
month intervals for the first 2 years and every 6 months thereafter. A
BCR was defined as a post-operative serum PSA of at least 0.4 ng/mL.
Irrespective of pathologic findings, suggesting a poor prognosis, none
of the patients received any adjuvant therapy until BCR was detected.
2 Immunohistochemical technique
RP specimens obtained from these patients were analyzed for the
expression of Bcl-2 using tissue microarray (TMA). Paraffin-
embedded formalin-fixed prostatectomy tissue blocks were cut in 3 μm
thicknesses onto silane-coated slides and heated for 30 minutes in an 57℃
oven. The tissue was then deparaffinized in xylene, rinsed well over
several ethanol washes (95%), and finally with distilled water. The
slides were then microwaved in EDTA buffer (pH 8.0) for 60 minutes
for antigen retrieval. Following a rinse with water, 3% hydrogen
peroxide was applied to the slides for 4 minutes at room temperature.
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Fig. 1. Prostate prognostic tissue microarray (TMA) containing specimens from 171 tumors. (A) TMA section stained with hematoxylin and
eosin (×100). (B) TMA section with Bcl-2 staining (×100). (a) Intensity of immunostaining for Bcl-2: negative group (×400). (b) Intensity of
immunostaining for Bcl-2: weak group (×400). (c) Intensity of immunostaining for Bcl-2: moderate group (×400). (d) Intensity of
immunostaining for Bcl-2: strong group (×400).
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Another rinse with Tris buffer was performed before the primary
Bcl-2 antibody (Dako co., Carpinteria, CA) was overlaid for 32
minutes at 42℃. The slides were again rinsed in Tris buffer twice,
then incubated with Biotin (iVIEW DAB detection kit, Ventana,
Tucson, AZ) for 10 minutes, rinsed again as before, and incubated
with streptavidin for 8 minutes. After a final rinse with Tris buffer,
chromogen (dimethylaminoazobenzene, Ventana) was applied for 8
minutes, followed by copper solution for 4 minutes. Counterstaining
was then performed with commercially prepared hematoxylin for 4
minutes. After post-counterstaining was performed with bluing
solution, the slides were dehydrated and coverslipped with Permount.
BenchMark XT (Ventana) was used for all staining. Two independent
uropathologists (WSP and EKH) viewed and interpreted the stained
slides without knowledge of patient outcome. As shown in Fig. 1, the
intensity of immunostaining for Bcl-2 was visually scored, and stratified
into four groups (negative, weak, moderate, and strong); each group
was defined as having no tumor cells, ＜10% the tumor cells, 10%
to 50% tumor cells, and ＞50% tumor cells, respectively. Any
cytoplasmic staining with Bcl-2 was considered positive, indicating
expression. Staining in the basal epithelial cells of normal prostate
epithelium served as an internal control.
3 End points and statistical analysis
Because there were too few patients with Bcl-2 weak, moderate,
and strong staining, it was necessary to combine the groups which
stained weak, moderate, and strong for this analysis. Contingency
table analysis and chi-square tests were used to determine the re-
lationship between the expression of Bcl-2 and other clinicopathologic
features. In addition, we determined the impact of Bcl-2 on BCR.
Recurrence-free survival curves were plotted according to the Kaplan-
Meier method. A log-rank test was applied to determine the relation-
ship between prognostic markers and BCR. A Cox proportional
hazard model with stepwise selection of the co-variates was used to
determine the parameters with the greatest influence on the risk of
BCR. The level of statistical significance was set at p＜0.05 (two-
sided), and the SPSS ver. 12.0 (SPSS Inc., Chicago, IL) was used
for the statistical analysis.
R e s u l t s
1 Patients
Data on all 171 patients were available. The mean age was 64.4
years (49 to 80 years). The patient characteristics are listed in Table
1. The pre-treatment serum PSA 4�10 group was most common in
our study. Pre- and post-operative Gleason scores ranged from 5 to
10. One hundred and sixty-seven patients had pre- and post-operative
Gleason scores. The post-operative Gleason scores were higher than
the pre-operative scores (p＜0.001). SVI, perineural invasion (PNI),
and lymphovascular invasion (LVI) were detected in 13 (7.8%), 104
(61.2%), and 16 (9.4%) patients, respectively. The surgical margin
positive rate was 34.7%.
2 Bcl-2 expression and clinicopathologic factors
Bcl-2 expression was immunohistologically confirmed in 42
patients (24.6%). The association between several clinicopathologic
factors and Bcl-2 expression in RP specimens was analyzed. Bcl-2
staining was not associated with PSA level, pre-operative Gleason
score, post-operative Gleason score, clinical stage, SVI, LVI and SMS.
Table 1. Patient characteristics
Classification No. of patients (%)
PSA* (ng/mL)
≤4.0 13 (7.6)
4.1-10.0 108 (63.2)
10.1-20.0 36 (21.1)
≥20.1 14 (8.2)
Pre-operative GS�
5-7 159 (93.0)
8-10 12 (7.0)
Post-operative GS
5-7 153 (91.6)
8-10 14 (8.4)
Clinical T stage
cT1 88 (51.5)
cT2 74 (43.3)
cT3 9 (5.3)
cT4 0 (0.0)
Pathologic T stage
pT2 126 (73.7)
pT3 45 (26.3)
pT4 0 (0.0)
Seminal vesicle invasion
Present 13 (7.8)
Absent 154 (92.2)
Perineural invasion
Present 104 (61.2)
Absent 66 (38.8)
Lymphovascular invasion
Present 16 (9.4)
Absent 151 (88.3)
Surgical margin status
Positive 58 (34.7)
Negative 109 (65.3)
Bcl-2
Positive 42 (24.6)
Negative 129 (75.4)
*prostate-specific antigen, �gleason score.
3 The impact of Bcl-2 on BCR
During the present observation period, BCR developed in 15 of
171 patients (8.8%); there were BCRs in 6 of 41 patients (14.6%)
with Bcl-2-positive RP specimens and in 9 of 126 patients (7.1%)
with Bcl-2-negative RP specimens. The Kaplan-Meier survival
estimates by Bcl-2 status are shown in Fig. 2. BCR-free survival in
patients with Bcl-2 positive specimens was significantly lower than
in patients with Bcl-2 negative specimens (p=0.036). At the time of
mean follow-up, 23.3 months, BCR-free survivals of Bcl-2 positive
and negative patients were 87.8% and 94.4% respectively. However,
these findings were not significant statistically. Furthermore, we
evaluated the predictive value of several clinicopathologic factors
for BCR. Eight variables recorded at the time of prostatectomy were
considered potential prognostic factors for BCR. By univariate Cox
proportional hazards analysis, the post-operative Gleason score ≥8
(p=0.002), extraprostatic extension (p=0.006), SVI (p＜0.001), LVI
(p=0.008), and Bcl-2 expression (p=0.039) significantly influenced the
time to BCR. Furthermore, the pre-operative Gleason score
(p=0.060) influenced BCR with borderline significance. Multivariate
Cox proportional hazards analysis revealed that BCR was signi-
ficantly associated with a high PSA level (hazard ratio [HR], 10.147;
p=0.047), SVI (HR, 42.613; p＜0.001), a positive surgical margin
(HR, 6.294; p=0.004), and Bcl-2 expression (HR, 4.503; p=0.012)
(Table 2).
D i s c u s s i o n
Carcinoma of the prostate varies greatly in biological behavior,
ranging from slowly progressive to highly aggressive metastasizing
tumors. The advent of immunohistochemical staining has led to
many studies using tumor biomarkers, but no marker has moved from
the research setting into the routine assessment of prostate carcinoma.
Several groups have studied Bcl-2 with conflicting results (12).
Given the alleged role of Bcl-2 expression for hormone resistance in
prostate cancer, such a result would be expected after anti-androgen
treatment (13-15). However, none of our patients had undergone
neoadjuvant or adjuvant anti-androgen therapy, thus our results
cannot be explained by this mechanism. Bauer et al. (11) reported
that increased expression of Bcl-2 correlates with higher rates of
BCR in patients who have undergone a RP for clinically-localized
prostate cancer. Further studies have also shown the ability of Bcl-2
to be of prognostic value for patients with organ-confined disease
(16,17). However, other studies have shown that Bcl-2 does not
have prognostic significance in prostate cancer patients (18).
In the current study, the routine clinical outcome predictors (pre-
operative PSA level, biopsy Gleason score, Gleason score in the RP
specimen, pathologic stage, SVI, PNI, LVI, SMS) and the expression
of Bcl-2 in specimens from 171 RPs performed during a 5-year
Cancer Res Treat. 2010;42(3):157-162
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Fig. 2. Kaplan-Meier biochemical recurrence (BCR)-free survival
curves according to the expression of Bcl-2.
Variables
Univariate Multivariate
HR* (95% CI�) p-value HR (95% CI) p-value
Conventional
PSA� (≤20.0 vs. ≥20.1§) 1.691 (0.220-12.990) 0.613 10.147 (1.032-99.781) 0.047
Pre-operative GS‖ (5-7 vs. 8-10§) 3.369 (0.949-11.964) 0.060 2.459 (0.473-12.773) 0.284
Post-operative GS (5-7 vs. 8-10§) 5.490 (1.862-16.184) 0.002 1.531 (0.325-7.202) 0.590
Extraprostatic extension (absence vs. presence§) 4.257 (1.512-11.984) 0.006 1.133 (0.258-4.963) 0.869
Seminal vesicle invasion (absence vs. presence§) 18.571 (6.565-52.531) ＜0.001 42.613 (8.120-223.631) ＜0.001
Lymphovascular invasion (absence vs. presence§) 4.343 (1.470-12.829) 0.008 2.683 (0.695-10.353) 0.152
Surgical margin status (negative vs. positive§) 2.012 (0.720-5.620) 0.182 6.294 (1.795-22.066) 0.004
Biomarker
Bcl-2 expression (negative vs. positive§) 2.712 (1.162-7.646) 0.039 4.503 (1.384-14.651) 0.012
Table 2. Univariate and multivariate analyses of prognostic factors for biochemical recurrence
*hazard ratio, �confidence interval, �prostate-specific antigen, §reference category, ‖gleason score.
period were compared. Based on the contingency table analysis and
chi-square tests, we did not find a significant relationship between
Bcl-2 expression and other parameters. Several previous studies showed
that Bcl-2 expression was not significantly associated with Gleason
score or stage. For example, in a report of patients with Stage B, C, or
D disease, Amirghofran et al. (19) found that Bcl-2 expression had
no relationship to prostate carcinoma stage or Gleason score.
Our analysis of conventional clinicopathologic parameters showed
that the post-operative Gleason score, extraprostatic extension, SVI,
and LVI were predictors of BCR by univariate analysis and that a
high PSA level, SVI, and positive surgical margin were significant
by multivariate analysis. A notable finding was that the expression
of Bcl-2 was an independent prognostic factor in univariate and
multivariate analyses. Furthermore, based on the Kaplan-Meier curve,
Bcl-2 expression was associated with a shortened BCR-free survival
in our series.
Several groups have studied Bcl-2, p53, and Ki-67 immunostaining,
but the results have been variable (11,16,20-22). The reasons for the
differences in these results include various definitions of BCR, di-
fferences in the sensitivity of the commercial antibodies, and car-
cinogenetic differences in marker expression. Marks et al. (23) reported
that prostate cancer specimens from native Japanese and Japanese-
American men were histologically-similar, but tissue biomarker
expression suggested differing mechanisms of carcinogenesis. In
our study, study populations were native Korean men. We concluded
that racial, ethnicity, and environmental differences affect expression
of biomarkers. Based on the results reported herein, Bcl-2 appears to
be an independent prognostic factor for BCR. This result implies
that Bcl-2 expression in a Korean population has unique clinical
significance.
A number of factors may have contributed to the differences
between the findings of the current study and earlier studies. First,
this study was a planned prospective study. Second, unlike the
previous studies, the current study used a well-defined and relatively
homogeneous group of patients. In a number of the earlier studies,
heterogeneous groups of patients with pathologic stages ranging
from pT1-pT4 were used, with some studies including patients with
anti-androgen therapy or multiple ethnic groups. As a result, substantial
variation in the risk of BCR would have related to tumor stage and
Gleason grade, and these biologic differences would have contributed
to potentially non-linear changes in biomarker expression that may
not have extrapolated to clinical subgroups. Third, in contrast to
earlier studies, two uropathologists (WSP and EKH) viewed the
stained slides without knowledge of patient outcome in our study.
This fact strengthens the significance of our study. In similarity to
previous studies, the total Bcl-2 positive rate of our study group was
24.6% (11). In contrast to previous studies, on the other hand, the
weak positive rate for our study group was 17.5%. We, thus, feel
that pathologist subjectivity may have affected the results of previous
studies. 
We would like to address several limitations of this study. First, a
sample size of 171 patients in as common a disease as prostate cancer
is not sufficiently large. Second, the average duration of follow-up
of 23.3 months was relatively short. This reduces the clinical signi-
ficance of our relatively low BCR rate. Third, it is possible that the
high rate of positive surgical margins and the low BCR rate may
have influenced the statistical analyses. Furthermore, although this
study focused on patients who were diagnosed with organ-confined
prostate cancer, the clinicopathologic features were relatively adverse
compared with the large series performed in Western country (24).
Nevertheless, the research focusing on Bcl-2 and other molecular
markers is worthwhile. Therefore, in the future, studies with larger
numbers of patients and longer-term follow-up will be required.
Fourth, the TMA has some limitations compared with real-time
PCR. The most important potential limitation is the small size of the
tissue sample (tissue volume). Thus, strong heterogeneity of the
tumor sample may not be reflective of the heterogeneity of the
tumor as a whole (18).
C o n c l u s i o n
The expression of Bcl-2 in RP specimens seems to be associated
with a significantly worse outcome, highlighting a potential clinical
role. Post-operative Bcl-2 could be a significant predictor of BCR in
patients undergoing RP. In addition, Bcl-2 expression may influence
the decision for adjuvant or salvage treatment.
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